Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar

4th October 2023 Uncategorised 0

Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
fkansteiner
Wed, 10/04/2023 – 10:34

More: Boehringer Ingelheim embraces dual-pricing tactic with launch of unbranded Humira biosimilar
Source: fierce